Latest Us Market News

Tetratherix Limited has raised approximately $5 million to fast-track its Tutelix prostate spacer into pivotal clinical trials across Australia and the US, aiming to improve radiation therapy for prostate cancer patients.

Cyclopharm Limited has responded to ASX queries clarifying the material significance of its Technegas® contract with the US National Institutes of Health, while confirming robust progress in expanding its US footprint.

New Frontier Minerals has confirmed significant high-grade tungsten mineralisation at its Harts Range Project in the Northern Territory, complementing its rare earth focus and capitalising on a soaring tungsten market. Meanwhile, its Pomme Rare Earth Project in Quebec advances with promising metallurgical testing underway.

LTR Pharma has finalised recruitment for its Phase II clinical trial of SPONTAN, a rapid-acting intranasal spray for erectile dysfunction, with initial results expected in the second quarter of 2026.

Peak Processing Limited has renewed and expanded its manufacturing agreement with Electric Brands, securing an expected annual production of approximately 1.4 million Sweet Justice cannabis beverage units. This deal reinforces Peak’s position in North America’s regulated cannabis beverage market and supports growth in Canada and the US.

Lindian Resources has executed a binding agreement to acquire full ownership of a rare earths processing facility in Kazakhstan, marking a strategic shift from concentrate production to higher-value Mixed Rare Earth Carbonate (MREC) output by late 2026.

PainChek Limited reported a half-year loss of AUD 4.7 million but achieved a major regulatory milestone with FDA clearance for its Adult App, unlocking significant US market opportunities. The company also completed a share consolidation and raised capital to support growth.

Thrive Tribe Technologies reported a $1.8 million half-year loss, driven by a major software impairment and ongoing operational challenges, while raising over $1.5 million in fresh capital to support its evolving business model.

Lumos Diagnostics reported a 74% increase in its half-year loss to US$4.88 million, despite strong progress with its FebriDx diagnostic test and a landmark US distribution agreement. The company awaits a critical FDA decision that could unlock significant revenue growth.

HighCom Limited has revealed a sharp downturn in its half-year results, with revenue plunging 59% and a $6.8 million loss after tax, driven by US government shutdown impacts. The company is banking on new lightweight XTclave® armour products to fuel a recovery in the second half of FY26.

Bubs Australia has delivered a robust first half for FY26, powered by a 48% revenue surge in the US, prompting an upgrade to its full-year earnings guidance.

BetMakers Technology Group Ltd reported an 11.4% rise in half-year revenue to $46.1 million alongside a dramatic 80% reduction in losses, setting the stage for accelerated global growth and a strategic US market push.